Gates Industrial Corporation Ltd. will announce its third-quarter 2026 earnings before the market opens on October 30, 2026. Management will hold a webcast and conference call at 10:00 a.m. Eastern time the same day to discuss the financial results. Investors can access the call via phone or live webcast on the company’s website. An audio replay will be available until November 6, 2026. This event provides insights into Gates Industrial's performance and outlook across its global manufacturing operations.
Gates Industrial's upcoming third-quarter 2026 earnings announcement is noted here with Pluang's Industrials sector data as context. Among 93 priced US Industrials stocks on Pluang as of Oct 07, 2026 03:12 WIB, 56 advanced while 34 declined. Notably, American Superconductor Corporation gained 6.14% at USD 31.82, contrasting with Flux Power Holdings Inc's 6.78% drop to USD 0.48, and Comfort Systems USA Inc rose 5.95% to USD 1,815.00, with typical hold times ranging from 19 to 41 days.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
U.S. spot Solana ETFs experienced $3.7 million in net outflows on October 6, marking the second consecutive day of withdrawals. The Grayscale Solana Trust was the main contributor to this decline, while six other funds showed no net flow. Although th...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
